Ibrutinib Triggers Matriptase to Preserve CD19 and Block Antigen Escape in B-Cell Malignancy
New research shows that the BTK inhibitor ibrutinib activates the protease matriptase in malignant B cells, preserving surface CD19 and ...
New research shows that the BTK inhibitor ibrutinib activates the protease matriptase in malignant B cells, preserving surface CD19 and ...
A systematic review and meta-analysis of 70 clinical studies finds that newer BTK inhibitors acalabrutinib and zanubrutinib outperform ibrutinib as ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine